Metropolitan Life Insurance CO Aligos Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$2.08 - $12.2 $13,534 - $79,385	-6,507 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$11.48 - $17.69 $74,700 - $115,108	6,507 New	6,507 $77,000
Q3 2021 Jun 21, 2023	BUY	$14.57 - $17.72 $94,806 - $115,304	6,507 New	6,507 $100,000
Q3 2021 Mar 30, 2023	BUY	$14.57 - $17.72 $2,127 - $2,587	146 Added 2.3%	6,507 $100,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $2,127 - $2,587	146 Added 2.3%	6,507 $101,000
Q2 2021 Mar 30, 2023	BUY	$20.3 - $33.6 $129,128 - $213,729	6,361 New	6,361 $129,000
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $129,128 - $213,729	6,361 New	6,361 $130,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.